Avid Bioservices, Inc.

Today, ladies and gentlemen, welcome to the AVID Bioservices First Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we'll conduct a question and answer session, and instructions will follow at that time. As a reminder, this call may be recorded. I would now like to hand the conference over to Tim Brons of AVID Investors Relations Group. Please go ahead.

Thank you. Good afternoon, and thank you for joining us. On today's call, we have Nick Green, President and CEO Dan Hart, Chief Financial Officer, and Matt Quitniak, AVID's Chief Commercial Officer. Today, we will be providing an overview of AVID Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended July 31st, 2022. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, September 6th, 2022 will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release in this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at avidbio.com. With that, I will turn the call over to Nick Green, Abbott's President and CEO.

Thank you, Tim, and thank you to everyone who has dialed in and to those who are participating today via webcast. I am pleased to report that the momentum and growth achieved during fiscal 22 continued into the first quarter of fiscal 23. During the period, we achieved the highest quarterly revenue in the company's history. In connection with this achievement, our commercial team had another exceptional quarter, signing multiple new project agreements, and as a result, pushed our backlog to a new record level. With respect to our facilities, Our expansion work continues to progress according to schedule. During the first quarter, we initiated equipment validation in our Myford South facility and continued to advance construction of our cell and gene therapy facility, which included launching our analytical and process development capabilities for this business. During the period, we also announced the expansion of our process development capabilities for the mammalian cell business, which we expect to come online in quarter one of calendar 2023. Matt and I will provide additional details on the business development and operations for the period following an overview of our first quarter fiscal 23 financial results. And for that, I'll turn the call over to Dan.